Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes

Ying Xiong, Dong Sun, Yao Liu, Yanqing Fan, Lingyun Zhao, Xiaoming Li, Wenzhen Zhu, Ying Xiong, Dong Sun, Yao Liu, Yanqing Fan, Lingyun Zhao, Xiaoming Li, Wenzhen Zhu

Abstract

Objectives: In late December 2019, an outbreak of coronavirus disease (COVID-19) in Wuhan, China was caused by a novel coronavirus, newly named severe acute respiratory syndrome coronavirus 2. We aimed to quantify the severity of COVID-19 infection on high-resolution chest computed tomography (CT) and to determine its relationship with clinical parameters.

Materials and methods: From January 11, 2020, to February 5, 2020, the clinical, laboratory, and high-resolution CT features of 42 patients (26-75 years, 25 males) with COVID-19 were analyzed. The initial and follow-up CT, obtained a mean of 4.5 days and 11.6 days from the illness onset were retrospectively assessed for the severity and progression of pneumonia. Correlations among clinical parameters, initial CT features, and progression of opacifications were evaluated with Spearman correlation and linear regression analysis.

Results: Thirty-five patients (83%) exhibited a progressive process according to CT features during the early stage from onset. Follow-up CT findings showed progressive opacifications, consolidation, interstitial thickening, fibrous strips, and air bronchograms, compared with initial CT (all P < 0.05). Before regular treatments, there was a moderate correlation between the days from onset and sum score of opacifications (R = 0.68, P < 0.01). The C-reactive protein, erythrocyte sedimentation rate, and lactate dehydrogenase showed significantly positive correlation with the severity of pneumonia assessed on initial CT (Rrange, 0.36-0.75; P < 0.05). The highest temperature and the severity of opacifications assessed on initial CT were significantly related to the progression of opacifications on follow-up CT (P = 0.001-0.04).

Conclusions: Patients with the COVID-19 infection usually presented with typical ground glass opacities and other CT features, which showed significant correlations with some clinical and laboratory measurements. Follow-up CT images often demonstrated progressions during the early stage from illness onset.

Conflict of interest statement

Conflicts of interest and sources of funding: none declared.

Figures

FIGURE 1
FIGURE 1
A1–A3, The HRCT images at admission of a 44-year-old male patient (5 days from onset). Multiple ground glass opacities (GGOs) and GGO with interlobular septal thickening (like reticulation or “paving stone sign”; boxes) and thin fibrous stripes (arrow) are shown in different cross-sections. B1–B3, The HRCT images of a 38-year-old male patient, who is also medical personnel (9 days from onset). Diffuse opacities and consolidation, as well as air bronchograms (arrows) can be seen.
FIGURE 2
FIGURE 2
A, The differences in area and density of the max lesion in cross-section between the initial and follow-up CT. B, Before admission and treatments, the sum score was positively correlated with the days from onset to initial CT (with age and sex as covariates, R = 0.68, P < 0.01). After regular treatments, the correlation was no longer significant (P = 0.19). C, Three different cases showing their max lesion in cross-section in the initial and follow-up CT.
FIGURE 3
FIGURE 3
A case with progression after admission. A1–A2, The HRCT images of a 57-year-old female patient (4 days from onset). Multiple GGO distributed bilaterally. B1–B2, Three days later, more opacities, also with larger size, were seen bilaterally.
FIGURE 4
FIGURE 4
A case of slight improvement after admission. A1–A2, The HRCT images of a 56-year-old female patient (9 days from onset). Multiple GGO with interstitial thickening and thin fibrous stripes are shown. B1–B2, Six days later, the lesion size is smaller, and the density is slightly increased, also with more fibrous stripes. Arrows indicated the abnormalities.
FIGURE 5
FIGURE 5
The most serious patients are usually accompanied by acute respiratory distress syndrome (A1–A2, a 57-year-old female patient, 18 days from onset; B1–B2, a 75-year-old male patient, 15 days from onset). There are diffuse lesions in the lungs bilaterally, which showed as “white lungs.”
FIGURE 6
FIGURE 6
Positive relationships were shown (A) between lactate dehydrogenase and sum score of opacifications (R = 0.78, P < 0.001) and (B) between C-reactive protein and area of max lesion in cross-section (R = 0.65, P = 0.002). R correlation coefficients are calculated using partial correlation with age and sex as covariates.

References

    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet. 2020;395:497–506.
    1. International Committee on Taxonomy of Viruses. Naming the 2019 Coronavirus Available at: . Accessed February 11, 2020.
    1. World Health Organization. Novel coronavirus(2019-nCoV): situation report - 23 Available at: . Accessed February 12, 2020.
    1. Mahase E. China coronavirus: WHO declares international emergency as death toll exceeds 200. BMJ. 2020;368:m408.
    1. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523.
    1. Sun K, Chen J, Viboud C. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. The Lancet Digital Health. 2020.
    1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020.
    1. Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus–the species and its viruses, a statement of the coronavirus study group. BioRxiv. 2020.
    1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020.
    1. China National Health Commission Diagnosis and treatment of pneumonitis caused by new coronavirus (trial version 6). Available at: . Accessed February 19, 2020.
    1. Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. 2020;200432.
    1. Xie X, Zhong Z, Zhao W, et al. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology. 2020;200343.
    1. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020.
    1. WHO Preliminary clinical description of severe acute respiratory syndrome. Available at: . Accessed March 21, 2003.
    1. Lei J, Li J, Li X, et al. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;200236.
    1. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner society: glossary of terms for thoracic imaging. Radiology. 2008;246:697–722.
    1. Wong KT, Antonio GE, Hui DS, et al. Thin-section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease. Radiology. 2003;228:395–400.
    1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
    1. Song F, Shi N, Shan F, et al. Emerging coronavirus 2019-nCoV pneumonia. Radiology. 2020;200274.
    1. Wang Q, Zhang Z, Shi Y, et al. Emerging H7N9 influenza a (novel reassortant avian-origin) pneumonia: radiologic findings. Radiology. 2013;268:882–889.
    1. Ajlan AM, Ahyad RA, Jamjoom LG, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) infection: chest CT findings. Am J Roentgenol. 2014;203:782–787.
    1. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014;59:118–128.
    1. Huang KJ, Su IJ, Theron M, et al. An interferon-γ-related cytokine storm in SARS patients. J Med Virol. 2005;75:185–194.
    1. Tsang OT, Chau TN, Choi KW, et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis. 2003;9:1381–1387.
    1. Ahn S, Kim WY, Kim SH, et al. Role of procalcitonin and C-reactive protein in differentiation of mixed bacterial infection from 2009 H1N1 viral pneumonia. Influenza Other Respi Viruses. 2011;5:398–403.
    1. Chang YC, Yu CJ, Chang SC, et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT. Radiology. 2005;236:1067–1075.
    1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. Medrxiv. 2020.
    1. Pan F, Ye T, Sun P, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology. 2020:200370.

Source: PubMed

3
Abonnieren